A long-lasting injectable treatment for preventing organ transplant rejection
Official title: Long-acting injectable tacrolimus for chronic immunosuppression
Funded at Auritec Pharmaceuticals, INC. · NIH-10662560 · Data updated 2026-11-12
This study is testing a new long-lasting injection of tacrolimus, a medicine that helps prevent organ rejection in transplant patients, so you won’t have to take daily pills and can maintain steady levels of the drug for a whole month after just one shot.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Auritec Pharmaceuticals, INC. NIH-funded |
| Lab location | 1 site (Pasadena, United States) |
| Project start | July 8, 2022 |
| Project end | June 30, 2025 |
| Funding year | 2023 |
| Award (this year) | $1,023,600 |
| NIH project number | 5R44AI170362-02 |
| Project ID | NIH-10662560 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have undergone organ transplantation and require immunosuppressive therapy to prevent organ rejection.
✕Less likely to help
Patients who are not organ transplant recipients or those who do not require immunosuppressive therapy may not benefit from this research.
What this research studies
This research focuses on developing a long-acting injectable form of tacrolimus, a medication used to prevent organ rejection in transplant recipients. The new formulation aims to provide consistent therapeutic levels of the drug for 30 days after a single injection, addressing issues of medication adherence associated with daily oral dosing. By utilizing innovative technology, the study seeks to improve patient outcomes and reduce the risk of organ rejection due to fluctuating drug levels. Patients will be monitored for their response to this new treatment approach.
Why it matters
Potential benefit: If successful, this research could significantly improve medication adherence and graft survival rates in organ transplant recipients.
How similar studies have gone: Previous studies have shown success with long-acting injectable formulations in other therapeutic areas, suggesting potential for this novel approach in immunosuppression.
Where this research is happening
-
Auritec Pharmaceuticals, INC.
Pasadena, United States Active
Researchers
- Principal investigator: Smith, Thomas J. — Auritec Pharmaceuticals, INC.
- Study coordinator: Smith, Thomas J.
Related research
Other NIH-funded projects on the same topics.
-
Vascular signals from brain blood vessels influence immune-suppressing cells in glioblastoma
This grant explores how blood vessel cells in glioblastoma shape immune cells to help the tumor grow, with the aim of making immunotherapies work better for patients.
-
Vascularized niche with local immune protection to transplant insulin-producing cells for Type 1 diabetes
A new approach aims to transplant insulin-producing cells inside a vascularized pocket with local drug delivery to keep them alive and functioning without full-body immune suppression.
-
AHR-driven immunosuppression in glioblastoma and new therapeutic targets
A personalized cancer study aims to understand why glioblastoma suppresses the immune system and to find ways to boost anti-tumor immunity in patients with this brain tumor.
-
Fibroblast-made GABA fuels PDAC immune suppression
In people with pancreatic cancer, this study explores how a specific cell type in the tumor environment uses a brain-like chemical (GABA) to dampen immune attack against the cancer.
-
Biomarker-guided reduction of immunosuppression after liver transplant
A multicenter trial tests whether using blood biomarkers to guide tapering of immunosuppression in adults with liver transplants can keep people healthy while lowering drug exposure.
-
Understanding and Overcoming T cell Immunosuppression in Glioblastoma (GBM)
A large research program is looking at how glioblastoma tumors weaken immune responses and how to boost immune cells to fight GBM.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.